Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients
This study has been completed.
Sponsor:
Ablynx
Information provided by (Responsible Party):
Ablynx
ClinicalTrials.gov Identifier:
NCT01284569
First received: January 21, 2011
Last updated: February 26, 2013
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |